Awards

CIMT Lifetime Achievement Award

The CIMT Lifetime Achievement Award honors a European researcher who has significantly contributed to the advancement of cancer immunotherapy. The award was inaugurated in 2017 and is bestowed every other year.

2019

On May 21, 2019, Wolf Herman Fridman was honored for his outstanding contribution to a deeper understanding of cancer immunology and the tumor environment. His broad research interests over a long career have influenced facets in the field, from basic cancer immunology to clinical prognosis. His work and mentorship have given rise to a new generation of scientific leaders in European cancer immunology. Wolf Fridman is professor emeritus at Paris Descartes University as well as the founder of Cordeliers Research Centre, and president of the Canceropole Ile de France.


2017

In 2017, the CIMT Awards Committee has chosen Cornelis Melief to be the first recipient of this biennial award that celebrates the dedication, ingenuity, and impactful success of a researcher who has dedicated his life’s work to finding immunological treatment options for cancer patients. Internationally recognized for his insights into the relationship between tumors and the immune system and for his clinical research and development of innovative cell therapies and therapeutic vaccines, Cornelis Melief has provided leadership for a generation of European scientists.

 
683_CIMT_160518.jpg
 

CIMT 2018 Poster Awards


Tumor Biology
Christof Smith, University of North Carolina at Chapel Hill
Abstract #110

Therapeutic Vaccination
Adam Grippin, University of Florida
Abstract #011

Improving Immunity
Daniel Baumann, German Cancer Research Center DKFZ
Abstract #175

Immunomonitoring
Jonas Bochem, University Medical Center Tübingen
Abstract #034

Cellular Therapy
Julien Schmidt, University of Lausanne
Abstract #159

“TCR-pMHC 2D affinity and bond lifetime under force correlate with tumor-specific CD8 T cell responsiveness“


New Targets and New Leads
Chloe Chong, Ludwig Center for Cancer Research
Abstract #207

“Mass spectrometry-based antigen discovery expands the cancerimmunopeptidome”